| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8219112 | International Journal of Radiation Oncology*Biology*Physics | 2014 | 7 Pages |
Abstract
WLI in adult patients with ES and lung metastases is well tolerated and is associated with freedom from PR of 45% at 3Â years. Given its acceptable toxicity and potential therapeutic effect, WLI for pulmonary metastases in ES should be considered for adults, as it is in pediatric patients. All patients should be advised to quit smoking before receiving WLI.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Dana L. BA, Kaled M. MD, Naamit K. MD, Suzanne L. MD,